Apnimed files for Nasdaq IPO under the ticker $APMD, three months after submitting its sleep apnea drug AD109 for FDA approval.
Apnimed is finally going forward with an IPO attempt after years of flirting with the milestone.
The Cambridge, MA-based biotech revealed its
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
ORLANDO — Among adults with mild to severe obstructive sleep apnea, those receiving AD109, an oral combination drug, vs. placebo…
HoneyNaps Receives U.S. FDA 510(k) Clearance for SOMNUM V3.0 for AI-Based Sleep-Disordered Breathing Analysis
Cardiology biotech Kardigan filed for a Nasdaq IPO under ticker {$KARD}, joining a growing roster of clinical-stage drug…
Scribe markets its Nasdaq IPO at a $14 midpoint for ~$96M net proceeds; Scholar Rock's apitegromab awaits an FDA call on Novo…
With a pediatric approval in hand for Afrezza, MannKind believes that it finally has the boost it needs to make an impact in the…
